PR86266

HYDERABAD, India, Oct. 26, 2020 /PRNewswire=KYODO JBN/ --

- Commences construction of new 75,000 sq. ft. facility in Hyderabad

- Augmenting India team to 170 biologists

    Sai Life Sciences, one of India's fastest growing Contract Research,

Development & Manufacturing Organizations [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=expansion-of-biology-capabilities-at-integrated-R&D-campus ]   (CRDMO), today announced plans to significantly expand its biology

capabilities at its integrated R&D campus in Hyderabad, India with a dedicated

75,000 sq. ft. facility and an augmented team of 170 biologists. The new

facility will house expanded in vitro and in vivo biology services, DMPK and

toxicology capabilities with the first set of labs scheduled to open in March 2021.

    Making the announcement, CEO & Managing Director of Sai Life Sciences,

Krishna Kanumuri said, "We aspire to deliver over 100 development candidates

for our innovator partners by 2025. Our growing discovery biology team

co-located with our teams in medicinal chemistry, process development, process

engineering and scale-up will enable us to accelerate our clients' discovery

programs through rapid turnaround times and shorter decision-making cycles."

    Sai Life Sciences has been steadily growing its biology capabilities to

complement its strong foundation in medicinal chemistry, DMPK and toxicology

for supporting its customers across the entire drug discovery journey from

target ID and validation to IND. Last year, the company opened its first

international R&D facility with a biology lab in Boston, USA. The Boston

Biology Lab [https://www.sailife.com/cambridge-usa/?utm_source=pr&utm_medium=web&utm_campaign=expansion-of-biology-capabilities-at-integrated-R&D-campus ] is designed to offer start-up and biotech companies in the region biology

services to address exploratory and custom biology needs. The expanding team of

biologists, DMPK & toxicology scientists in India works seamlessly with the

Boston team to present clients an optimal solution in terms of speed, cost and talent.

    The company's discovery services support a wide range of global innovator

companies from start-ups to large pharma companies, across a diverse set of

therapeutic areas including oncology, CNS, antivirals, and inflammation among

others. With a strong track record of enduring customer relationships averaging

10+ years, Sai Life Sciences has advanced 25+ programs to different clinical

phases (IND to Phase-III) with the average turnaround time from Hit/Lead to

Candidate being 18 months.

    Sai Life Sciences began a process of organizational transformation in 2019,

through the Sai Nxt initiative, reinventing itself as a new generation global

CRO/CDMO [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=expansion-of-biology-capabilities-at-integrated-R&D-campus ]. Guided by the insights and feedback from its customers, the company is

investing over US$150M (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing

facilities, induct top-notch global scientific and leadership talent, strengthen automation

and data systems, and above all raise the bar for safety, quality and customer focus.

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO/ CDMO [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=expansion-of-biology-capabilities-at-integrated-R&D-campus ] driven by a vision to support the launch of 25 new medicines by 2025.  

It works with innovator pharma and biotech companies globally, accelerating the

discovery, development and manufacture of complex small molecules. A pure-play

CDMO, Sai Life Sciences has served a diverse set of NCE development programs,

consistently delivering value based on its quality and responsiveness. Today,

it works with 7 of the top 10 large pharma companies, as well as several small

and mid-sized pharma & biotech companies. Sai Life Sciences is privately held

and backed by global investors, TPG Capital and HBM Healthcare Investments.

https://www.sailife.com 

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg 

    Photo: https://mma.prnewswire.com/media/1319765/Sai_Life_Sciences_Biology_facility.jpg 

    Source: Sai Life Sciences